Pfizer posts detailed phase 3 data on its Dupixent rival

Pfizer has posted detailed phase 3 results on its rival to Sanofi and Regeneron’s atopic dermatitis drug Dupixent. The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent for a major market.